Abstract

An appropriate cell source is essential for the clinical application of bioartificial liver (BAL) system. This study aimed to test a reversibly immortalized human hepatocyte line (HepLi-4) in our newly validated choanoid fluidized bed bioreactor based BAL in pigs with fulminant hepatic failure (FHF). 15 FHF pigs were allocated to three groups: a BAL group receiving BAL treatment with HepLi-4 cells; a sham BAL group receiving cell-free BAL treatment; and a FHF group receiving intensive care only. Expression of liver-specific genes in HepLi-4 cells before and after BAL was analyzed, adult human hepatocytes acted as a reference. In BAL group, Fischer index was higher and serum indirect bilirubin level was lower compared with two control groups. Survival time in BAL group was longer than that in two control groups, but the difference was not statistically significant. Gene expression analysis showed that the transcript levels of liver-specific genes in HepLi-4 were retained after BAL, but significant variations were observed between HepLi-4 and human hepatocytes. HepLi-4 showed beneficial metabolic effects on FHF pigs in BAL, but is still not an appropriate cell source for BAL. More insights into interpreting the conditions for hepatocyte differentiation are needed.

Key words: Reversible immortalization, hepatocytes, bioartificial liver, fulminant hepatic failure.

Abbreviation

 BAL, Bioartificial liver; FHF, fulminant hepatic failure; AC, alginate-chitosan; PERV, porcine endogenous retroviruses; SV40 LT, simian virus 40 large T antigen; BCAAs, branched chain amino acids; AAAs, aromatic amino acids; GS, glutamine synthetase; UGT1A1, uridine diphosphate glucuronyltransferase; ALB, albumin; GST-P, glutathione S-transferase P; β-actin, human beta-actin; HE, hepatic encephalopathy; RT-PCR, reverse transcription-polymerase chain reaction.